Extracellular matrix remodeling in idiopathic pulmonary fibrosis. It is the ‘bed’ that counts and not ‘the sleepers’

References

• Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.
   PubMed Web of Science ®Google Scholar
• Coultas DB, Zumwalt RE, Black WC, et al. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med. 1994;150(4):967–972.
   PubMed Web of Science ®Google Scholar
• Karakatsani A, Papakosta D, Rapti A, et al. Epidemiology of interstitial lung diseases in Greece. Respir Med. 2009;103(8):1122–1129.
   PubMed Web of Science ®Google Scholar
• American Thoracic S, European Respiratory S, American College of Chest P, Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001;134(2):136–151.
   PubMed Web of Science ®Google Scholar
• Rosas IO, Kaminski N. Update in diffuse parenchymal lung disease, 2013. Am J Respir Crit Care Med. 2015;191(3):270–274.
   PubMed Web of Science ®Google Scholar
• Tzouvelekis A, Kaminski N. Epigenetics in idiopathic pulmonary fibrosis. Biochem Cell Biol. 2015;93(2):159–170.
   PubMed Web of Science ®Google Scholar
• Ley B, Brown KK, Collard HR. Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2014;307(9):L681–91.
   PubMed Web of Science ®Google Scholar
• Willis BC, Liebler JM, Luby-Phelps K, et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol. 2005;166(5):1321–1332.
   PubMed Web of Science ®Google Scholar
• Dunsmore SE, Rannels DE. Extracellular matrix biology in the lung. Am J Physiol. 1996;270(1 Pt 1):L3–27.
   PubMed Web of Science ®Google Scholar
• Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci. 2010;123(Pt 24):4195–4200.
   PubMed Web of Science ®Google Scholar
• Thannickal VJ, Henke CA, Horowitz JC, et al. Matrix biology of idiopathic pulmonary fibrosis: a workshop report of the National Heart, Lung, and Blood Institute. Am J Pathol. 2014;184(6):1643–1651.
   PubMed Web of Science ®Google Scholar
• King TE Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–2092.
   PubMed Web of Science ®Google Scholar
• Bouros D. Pirfenidone for idiopathic pulmonary fibrosis. Lancet. 2011;377(9779):1727–1729.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082.
   PubMed Web of Science ®Google Scholar
• Nathan SD, Albera C, Bradford WZ, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. 2017;5(1):33–41.
   PubMed Web of Science ®Google Scholar
• Kolb M, Richeldi L, Behr J, et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax.  2016 Sep 26. pii: thoraxjnl-2016-208710.
   Web of Science ®Google Scholar
• Tzouvelekis A, Yu G, Lacks Lino Cardenas C, et al. SH2 domain-containing phosphatase-SHP-2 is a novel anti-fibrotic regulator in pulmonary fibrosis. Am J Respir Crit Care Med. 2017;15(4):500–514.
   PubMed Web of Science ®Google Scholar
• Tzouvelekis A, Herazo-Maya J, Sakamoto K, et al. Biomarkers in the evaluation and management of idiopathic pulmonary fibrosis. Curr Top Med Chem. 2016;16(14):1587–1598.
   PubMed Web of Science ®Google Scholar
• Spagnolo P, Sverzellati N, Rossi G, et al. Idiopathic pulmonary fibrosis: an update. Ann Med. 2015;47(1):15–27.
   PubMed Web of Science ®Google Scholar
• Bouros D, Tzouvelekis A. Idiopathic pulmonary fibrosis: on the move. Lancet Respir Med. 2014;2(1):17–19.
   PubMed Web of Science ®Google Scholar
• Tzouvelekis A, Paspaliaris V, Koliakos G, et al. A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. J Transl Med. 2013;11:171.
   PubMed Web of Science ®Google Scholar
• Oikonomou N, Mouratis MA, Tzouvelekis A, et al. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol. 2012;47(5):566–574.
   PubMed Web of Science ®Google Scholar
• Kolb M, Gauldie J, Bellaye PS. Editorial: extracellular matrix: the common thread of disease progression in fibrosis? Art Rheumatol. 2016;68(5):1053–1056.
   PubMed Web of Science ®Google Scholar
• Shimbori C, Gauldie J, Kolb M. Extracellular matrix microenvironment contributes actively to pulmonary fibrosis. Curr Opin Pulm Med. 2013;19(5):446–452.
   PubMed Web of Science ®Google Scholar
• Raghu G, Striker LJ, Hudson LD, et al. Extracellular matrix in normal and fibrotic human lungs. Am Rev Respir Dis. 1985;131(2):281–289.
   PubMed Web of Science ®Google Scholar
• Sugihara H, Toda S, Miyabara S, et al. Reconstruction of alveolus-like structure from alveolar type II epithelial cells in three-dimensional collagen gel matrix culture. Am J Pathol. 1993;142(3):783–792.
   PubMed Web of Science ®Google Scholar
• Shannon JM, Emrie PA, Fisher JH, et al. Effect of a reconstituted basement membrane on expression of surfactant apoproteins in cultured adult rat alveolar type II cells. Am J Respir Cell Mol Biol. 1990;2(2):183–192.
   PubMed Web of Science ®Google Scholar
• Harburger DS, Calderwood DA. Integrin signalling at a glance. J Cell Sci. 2009;122(Pt 2):159–163.
   PubMed Web of Science ®Google Scholar
• Bohnsack JF, Akiyama SK, Damsky CH, et al. Human neutrophil adherence to laminin in vitro. Evidence for a distinct neutrophil integrin receptor for laminin. J Exp Med. 1990;171(4):1221–1237.
   PubMed Web of Science ®Google Scholar
• Kurundkar A, Thannickal VJ. Redox mechanisms in age-related lung fibrosis. Redox Biol. 2016;9:67–76.
   PubMed Web of Science ®Google Scholar
• Romero Y, Bueno M, Ramirez R, et al. mTORC1 activation decreases autophagy in aging and idiopathic pulmonary fibrosis and contributes to apoptosis resistance in IPF fibroblasts. Aging Cell. 2016 Aug 6.
   PubMed Web of Science ®Google Scholar
• Yanai H, Shteinberg A, Porat Z, et al. Cellular senescence-like features of lung fibroblasts derived from idiopathic pulmonary fibrosis patients. Aging (Albany NY). 2015;7(9):664–672.
   PubMedGoogle Scholar
• Hinz B, Phan SH, Thannickal VJ, et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol. 2012;180(4):1340–1355.
   PubMed Web of Science ®Google Scholar
• Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol. 2003;200(4):500–503.
   PubMed Web of Science ®Google Scholar
• Phan SH. Biology of fibroblasts and myofibroblasts. Proc Am Thorac Soc. 2008;5(3):334–337.
   PubMedGoogle Scholar
• Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–890.
   PubMed Web of Science ®Google Scholar
• Borok Z. Role for alpha3 integrin in EMT and pulmonary fibrosis. J Clin Invest. 2009;119(1):7–10.
   PubMed Web of Science ®Google Scholar
• Willis BC, Borok Z. TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. American Journal of Physiology Lung Cellular and Molecular Physiology. 2007;293(3):L525–34.
   PubMed Web of Science ®Google Scholar
• Willis BC, Du Bois RM, Borok Z. Epithelial origin of myofibroblasts during fibrosis in the lung. Proc Am Thorac Soc. 2006;3(4):377–382.
   PubMedGoogle Scholar
• Trimble A, Gochuico BR, Markello TC, et al. Circulating fibrocytes as biomarker of prognosis in Hermansky-Pudlak syndrome. Am J Respir Crit Care Med. 2014;190(12):1395–1401.
   PubMed Web of Science ®Google Scholar
• Phillips RJ, Burdick MD, Hong K, et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest. 2004;114(3):438–446.
   PubMed Web of Science ®Google Scholar
• Tanjore H, Xu XC, Polosukhin VV, et al. Contribution of epithelial-derived fibroblasts to bleomycin-induced lung fibrosis. Am J Respir Crit Care Med. 2009;180(7):657–665.
   PubMed Web of Science ®Google Scholar
• Rock JR, Barkauskas CE, Cronce MJ, et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc Natl Acad Sci U S A. 2011;108(52):E1475–83.
   PubMed Web of Science ®Google Scholar
• Grimminger F, Gunther A, Vancheri C. The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45(5):1426–1433.
   PubMed Web of Science ®Google Scholar
• Zhao XK, Cheng Y, Liang Cheng M, et al. Focal adhesion kinase regulates fibroblast migration via integrin beta-1 and plays a central role in fibrosis. Sci Rep. 2016;6:19276.
   PubMed Web of Science ®Google Scholar
• Parker MW, Rossi D, Peterson M, et al. Fibrotic extracellular matrix activates a profibrotic positive feedback loop. J Clin Invest. 2014;124(4):1622–1635.
   Web of Science ®Google Scholar
• Adair-Kirk TL, Senior RM. Fragments of extracellular matrix as mediators of inflammation. Int J Biochem Cell Biol. 2008;40(6–7):1101–1110.
   PubMed Web of Science ®Google Scholar
• Clarke DL, Carruthers AM, Mustelin T, et al. Matrix regulation of idiopathic pulmonary fibrosis: the role of enzymes. Fibrogenesis Tissue Repair. 2013;6(1):20.
   PubMedGoogle Scholar
• Jiang D, Liang J, Fan J, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med. 2005;11(11):1173–1179.
   PubMed Web of Science ®Google Scholar
• Karampitsakos T, Woolard T, Bouros D, et al. Toll-like receptors in the pathogenesis of pulmonary fibrosis. Eur J Pharmacol. 2016 Jun 27. pii: S0014-2999(16)30404–30406.
   PubMedGoogle Scholar
• Kuntz RM, Saltzman WM. Neutrophil motility in extracellular matrix gels: mesh size and adhesion affect speed of migration. Biophys J. 1997;72(3):1472–1480.
   PubMed Web of Science ®Google Scholar
• Muro AF, Moretti FA, Moore BB, et al. An essential role for fibronectin extra type III domain A in pulmonary fibrosis. Am J Respir Crit Care Med. 2008;177(6):638–645.
   PubMed Web of Science ®Google Scholar
• Jakob SM, Pick R, Brechtefeld D, et al. Hematopoietic progenitor kinase 1 (HPK1) is required for LFA-1-mediated neutrophil recruitment during the acute inflammatory response. Blood. 2013;121(20):4184–4194.
   PubMed Web of Science ®Google Scholar
• Walzog B, Schuppan D, Heimpel C, et al. The leukocyte integrin Mac-1 (CD11b/CD18) contributes to binding of human granulocytes to collagen. Exp Cell Res. 1995;218(1):28–38.
   PubMed Web of Science ®Google Scholar
• Murray LA, Argentieri RL, Farrell FX, et al. Hyper-responsiveness of IPF/UIP fibroblasts: interplay between TGFbeta1, IL-13 and CCL2. Int J Biochem Cell Biol. 2008;40(10):2174–2182.
   PubMed Web of Science ®Google Scholar
• Mazur A, Holthoff E, Vadali S, et al. Cleavage of type I collagen by fibroblast activation protein-alpha enhances class a scavenger receptor mediated macrophage adhesion. Plos One. 2016;11(3):e0150287.
   PubMed Web of Science ®Google Scholar
• Naik PK, Bozyk PD, Bentley JK, et al. Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. American Journal of Physiology Lung Cellular and Molecular Physiology. 2012;303(12):L1046–56.
   PubMed Web of Science ®Google Scholar
• Pardo A, Selman M. Role of matrix metalloproteases in idiopathic pulmonary fibrosis. Fibrogenesis Tissue Repair. 2012;5(Suppl 1):S9.
   PubMedGoogle Scholar
• Uchida M, Shiraishi H, Ohta S, et al. Periostin, a matricellular protein, plays a role in the induction of chemokines in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2012;46(5):677–686.
   PubMed Web of Science ®Google Scholar
• Rozin GF, Gomes MM, Parra ER, et al. Collagen and elastic system in the remodelling process of major types of idiopathic interstitial pneumonias (IIP). Histopathology. 2005;46(4):413–421.
   PubMed Web of Science ®Google Scholar
• McKleroy W, Lee TH, Atabai K. Always cleave up your mess: targeting collagen degradation to treat tissue fibrosis. Am J Physiol Lung Cell Mol Physiol. 2013;304(11):L709–21.
   PubMed Web of Science ®Google Scholar
• Gerriets JE, Reiser KM, Last JA. Lung collagen cross-links in rats with experimentally induced pulmonary fibrosis. Biochim Biophys Acta. 1996;1316(2):121–131.
   PubMed Web of Science ®Google Scholar
• Okamoto M, Hoshino T, Kitasato Y, et al. Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. Eur Respir J. 2011;37(5):1119–1127.
   PubMed Web of Science ®Google Scholar
• Kulkarni T, O’Reilly P, Antony VB, et al. Matrix remodeling in pulmonary fibrosis and emphysema. Am J Respir Cell Mol Biol. 2016;54(6):751–760.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Huang X, Hecker L, et al. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J Clin Invest. 2013;123(3):1096–1108.
   PubMed Web of Science ®Google Scholar
• Froese AR, Shimbori C, Bellaye PS, et al. Stretch-induced activation of transforming growth factor-beta1 in pulmonary fibrosis. Am J Respir Crit Care Med. 2016;194(1):84–96.
   PubMed Web of Science ®Google Scholar
• Horiguchi M, Ota M, Rifkin DB. Matrix control of transforming growth factor-beta function. J Biochem. 2012;152(4):321–329.
   PubMed Web of Science ®Google Scholar
• Puthawala K, Hadjiangelis N, Jacoby SC, et al. Inhibition of integrin alpha(v)beta6, an activator of latent transforming growth factor-beta, prevents radiation-induced lung fibrosis. Am J Respir Crit Care Med. 2008;177(1):82–90.
   PubMed Web of Science ®Google Scholar
• Bonniaud P, Margetts PJ, Ask K, et al. TGF-beta and Smad3 signaling link inflammation to chronic fibrogenesis. J Immunology. 2005;175(8):5390–5395.
   PubMed Web of Science ®Google Scholar
• Bonniaud P, Kolb M, Galt T, et al. Smad3 null mice develop airspace enlargement and are resistant to TGF-beta-mediated pulmonary fibrosis. J Immunology. 2004;173(3):2099–2108.
   PubMed Web of Science ®Google Scholar
• Horan GS, Wood S, Ona V, et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med. 2008;177(1):56–65.
   PubMed Web of Science ®Google Scholar
• Henderson NC, Arnold TD, Katamura Y, et al. Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med. 2013;19(12):1617–1624.
   PubMed Web of Science ®Google Scholar
• Minagawa S, Lou J, Seed RI, et al. Selective targeting of TGF-beta activation to treat fibroinflammatory airway disease. Sci Transl Med. 2014;6(241):241ra79.
   PubMed Web of Science ®Google Scholar
• Leask A, Abraham DJ. The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem Cell Biol. 2003;81(6):355–363.
   PubMed Web of Science ®Google Scholar
• Sonnylal S, Xu S, Jones H, et al. Connective tissue growth factor causes EMT-like cell fate changes in vivo and in vitro. J Cell Sci. 2013;126(Pt 10):2164–2175.
   PubMed Web of Science ®Google Scholar
• Ponticos M, Holmes AM, Shi-Wen X, et al. Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen. Arthritis Rheum. 2009;60(7):2142–2155.
   PubMed Web of Science ®Google Scholar
• Bonniaud P, Martin G, Margetts PJ, et al. Connective tissue growth factor is crucial to inducing a profibrotic environment in “fibrosis-resistant” BALB/c mouse lungs. Am J Respir Cell Mol Biol. 2004;31(5):510–516.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Stetler-Stevenson WG, Fleming MV, et al. Immunohistochemical study of metalloproteinases and their tissue inhibitors in the lungs of patients with diffuse alveolar damage and idiopathic pulmonary fibrosis. Am J Pathol. 1996;149(4):1241–1256.
   PubMed Web of Science ®Google Scholar
• Fukuda Y, Ishizaki M, Kudoh S, et al. Localization of matrix metalloproteinases-1, −2, and −9 and tissue inhibitor of metalloproteinase-2 in interstitial lung diseases. Lab Invest. 1998;78(6):687–698.
   PubMed Web of Science ®Google Scholar
• Selman M, Ruiz V, Cabrera S, et al. TIMP-1, −2, −3, and −4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment? Am J Physiol Lung Cell Mol Physiol. 2000;279(3):L562–74.
   PubMed Web of Science ®Google Scholar
• Fulmer JD, Bienkowski RS, Cowan MJ, et al. Collagen concentration and rates of synthesis in idiopathic pulmonary fibrosis. Am Rev Respir Dis. 1980;122(2):289–301.
   PubMed Web of Science ®Google Scholar
• Selman M, Montano M, Ramos C, et al. Concentration biosynthesis and degradation of collagen in idiopathic pulmonary fibrosis. Thorax. 1986;41(5):355–359.
   PubMed Web of Science ®Google Scholar
• Craig VJ, Zhang L, Hagood JS, et al. Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 2015;53(5):585–600.
   PubMed Web of Science ®Google Scholar
• Zuo F, Kaminski N, Eugui E, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci U S A. 2002;99(9):6292–6297.
   PubMed Web of Science ®Google Scholar
• Fujishima S, Shiomi T, Yamashita S, et al. Production and activation of matrix metalloproteinase 7 (matrilysin 1) in the lungs of patients with idiopathic pulmonary fibrosis. Arch Pathol Lab Med. 2010;134(8):1136–1142.
   PubMed Web of Science ®Google Scholar
• Pardo A, Cabrera S, Maldonado M, et al. Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis. Respir Res. 2016;17:23.
   PubMed Web of Science ®Google Scholar
• Zhang L, Rice AB, Adler K, et al. Vanadium stimulates human bronchial epithelial cells to produce heparin-binding epidermal growth factor-like growth factor: a mitogen for lung fibroblasts. Am J Respir Cell Mol Biol. 2001;24(2):123–131.
   PubMed Web of Science ®Google Scholar
• Rims CR, McGuire JK. Matrilysin (MMP-7) catalytic activity regulates beta-catenin localization and signaling activation in lung epithelial cells. Exp Lung Res. 2014;40(3):126–136.
   PubMed Web of Science ®Google Scholar
• Manicone AM, Huizar I, McGuire JK. Matrilysin (matrix metalloproteinase-7) regulates anti-inflammatory and antifibrotic pulmonary dendritic cells that express CD103 (alpha(E)beta(7)-integrin). Am J Pathol. 2009;175(6):2319–2331.
   PubMed Web of Science ®Google Scholar
• Selman M, Pardo A, Barrera L, et al. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2006;173(2):188–198.
   PubMed Web of Science ®Google Scholar
• Yu G, Kovkarova-Naumovski E, Jara P, et al. Matrix metalloproteinase-19 is a key regulator of lung fibrosis in mice and humans. Am J Respir Crit Care Med. 2012;186(8):752–762.
   PubMed Web of Science ®Google Scholar
• Maher TM, Evans IC, Bottoms SE, et al. Diminished prostaglandin E2 contributes to the apoptosis paradox in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2010;182(1):73–82.
   PubMed Web of Science ®Google Scholar
• Jara P, Calyeca J, Romero Y, et al. Matrix metalloproteinase (MMP)-19-deficient fibroblasts display a profibrotic phenotype. American Journal of Physiology Lung Cellular and Molecular Physiology. 2015;308(6):L511–22.
   PubMed Web of Science ®Google Scholar
• Stracke JO, Hutton M, Stewart M, et al. Biochemical characterization of the catalytic domain of human matrix metalloproteinase 19. Evidence for a role as a potent basement membrane degrading enzyme. J Biol Chem. 2000;275(20):14809–14816.
   PubMed Web of Science ®Google Scholar
• Sadowski T, Dietrich S, Koschinsky F, et al. Matrix metalloproteinase 19 processes the laminin 5 gamma 2 chain and induces epithelial cell migration. Cell Mol Life Sci. 2005;62(7–8):870–880.
   PubMed Web of Science ®Google Scholar
• Yamashita CM, Dolgonos L, Zemans RL, et al. Matrix metalloproteinase 3 is a mediator of pulmonary fibrosis. Am J Pathol. 2011;179(4):1733–1745.
   PubMed Web of Science ®Google Scholar
• Maeda S, Dean DD, Gomez R, et al. The first stage of transforming growth factor beta1 activation is release of the large latent complex from the extracellular matrix of growth plate chondrocytes by matrix vesicle stromelysin-1 (MMP-3). Calcif Tissue Int. 2002;70(1):54–65.
   PubMed Web of Science ®Google Scholar
• Heljasvaara R, Nyberg P, Luostarinen J, et al. Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. Exp Cell Res. 2005;307(2):292–304.
   PubMed Web of Science ®Google Scholar
• Selman M, Carrillo G, Estrada A, et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. Plos One. 2007;2(5):e482.
   PubMed Web of Science ®Google Scholar
• Ramirez G, Hagood JS, Sanders Y, et al. Absence of Thy-1 results in TGF-beta induced MMP-9 expression and confers a profibrotic phenotype to human lung fibroblasts. Lab Invest. 2011;91(8):1206–1218.
   PubMed Web of Science ®Google Scholar
• Betsuyaku T, Fukuda Y, Parks WC, et al. Gelatinase B is required for alveolar bronchiolization after intratracheal bleomycin. Am J Pathol. 2000;157(2):525–535.
   PubMed Web of Science ®Google Scholar
• Andrews KL, Betsuyaku T, Rogers S, et al. Gelatinase B (MMP-9) is not essential in the normal kidney and does not influence progression of renal disease in a mouse model of Alport syndrome. Am J Pathol. 2000;157(1):303–311.
   PubMed Web of Science ®Google Scholar
• Pilewski JM, Liu L, Henry AC, et al. Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Am J Pathol. 2005;166(2):399–407.
   PubMed Web of Science ®Google Scholar
• Ruiz XD, Mlakar LR, Yamaguchi Y, et al. Syndecan-2 is a novel target of insulin-like growth factor binding protein-3 and is over-expressed in fibrosis. Plos One. 2012;7(8):e43049.
   PubMed Web of Science ®Google Scholar
• Hall MC, Young DA, Waters JG, et al. The comparative role of activator protein 1 and Smad factors in the regulation of Timp-1 and MMP-1 gene expression by transforming growth factor-beta 1. J Biol Chem. 2003;278(12):10304–10313.
   PubMed Web of Science ®Google Scholar
• Chen P, McGuire JK, Hackman RC, et al. Tissue inhibitor of metalloproteinase-1 moderates airway re-epithelialization by regulating matrilysin activity. Am J Pathol. 2008;172(5):1256–1270.
   PubMed Web of Science ®Google Scholar
• Kim KH, Burkhart K, Chen P, et al. Tissue inhibitor of metalloproteinase-1 deficiency amplifies acute lung injury in bleomycin-exposed mice. Am J Respir Cell Mol Biol. 2005;33(3):271–279.
   PubMed Web of Science ®Google Scholar
• Koskivirta I, Kassiri Z, Rahkonen O, et al. Mice with tissue inhibitor of metalloproteinases 4 (Timp4) deletion succumb to induced myocardial infarction but not to cardiac pressure overload. J Biol Chem. 2010;285(32):24487–24493.
   PubMed Web of Science ®Google Scholar
• Ruiz V, Ordonez RM, Berumen J, et al. Unbalanced collagenases/TIMP-1 expression and epithelial apoptosis in experimental lung fibrosis. Am J Physiol Lung Cell Mol Physiol. 2003;285(5):L1026–36.
   PubMed Web of Science ®Google Scholar
• Howell DC, Johns RH, Lasky JA, et al. Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis. Am J Pathol. 2005;166(5):1353–1365.
   PubMed Web of Science ®Google Scholar
• Wygrecka M, Dahal BK, Kosanovic D, et al. Mast cells and fibroblasts work in concert to aggravate pulmonary fibrosis: role of transmembrane SCF and the PAR-2/PKC-alpha/Raf-1/p44/42 signaling pathway. Am J Pathol. 2013;182(6):2094–2108.
   PubMed Web of Science ®Google Scholar
• Wygrecka M, Kwapiszewska G, Jablonska E, et al. Role of protease-activated receptor-2 in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(12):1703–1714.
   PubMed Web of Science ®Google Scholar
• Chambers RC, Laurent GJ. Coagulation cascade proteases and tissue fibrosis. Biochem Soc Trans. 2002;30(2):194–200.
   PubMed Web of Science ®Google Scholar
• Staab-Weijnitz CA, Fernandez IE, Knuppel L, et al. FK506-binding protein 10, a potential novel drug target for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2015;192(4):455–467.
   PubMed Web of Science ®Google Scholar
• Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol. 2003;4(2):140–156.
   PubMed Web of Science ®Google Scholar
• Stephens P, Grenard P, Aeschlimann P, et al. Crosslinking and G-protein functions of transglutaminase 2 contribute differentially to fibroblast wound healing responses. J Cell Sci. 2004;117(Pt 15):3389–3403.
   PubMed Web of Science ®Google Scholar
• Olsen KC, Sapinoro RE, Kottmann RM, et al. Transglutaminase 2 and its role in pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(6):699–707.
   PubMed Web of Science ®Google Scholar
• Barry-Hamilton V, Spangler R, Marshall D, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med. 2010;16(9):1009–1017.
   PubMed Web of Science ®Google Scholar
• Liu F, Mih JD, Shea BS, et al. Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression. J Cell Biol. 2010;190(4):693–706.
   PubMed Web of Science ®Google Scholar
• Cheng T, Liu Q, Zhang R, et al. Lysyl oxidase promotes bleomycin-induced lung fibrosis through modulating inflammation. J Mol Cell Biol. 2014;6(6):506–515.
   PubMed Web of Science ®Google Scholar
• Li S, Yang X, Li W, et al. N-acetylcysteine downregulation of lysyl oxidase activity alleviating bleomycin-induced pulmonary fibrosis in rats. Respiration. 2012;84(6):509–517.
   PubMed Web of Science ®Google Scholar
• Kamikawaji K, Seki N, Watanabe M, et al. Regulation of LOXL2 and SERPINH1 by antitumor microRNA-29a in lung cancer with idiopathic pulmonary fibrosis. J Hum Genet. 2016 Dec;61(12):985–993.
   Web of Science ®Google Scholar
• Nishi Y, Sano H, Kawashima T, et al. Role of galectin-3 in human pulmonary fibrosis. Allergol Int. 2007;56(1):57–65.
   PubMedGoogle Scholar
• Mackinnon AC, Gibbons MA, Farnworth SL, et al. Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med. 2012;185(5):537–546.
   PubMed Web of Science ®Google Scholar
• Van Der Meeren A, Moureau A, Griffiths NM. Macrophages as key elements of mixed-oxide [U-Pu(O2)] distribution and pulmonary damage after inhalation? Int J Radiat Biol. 2014;90(11):1095–1103.
   PubMed Web of Science ®Google Scholar
• Malaviya R, Venosa A, Hall L, et al. Attenuation of acute nitrogen mustard-induced lung injury, inflammation and fibrogenesis by a nitric oxide synthase inhibitor. Toxicol Appl Pharmacol. 2012;265(3):279–291.
   PubMed Web of Science ®Google Scholar
• Li LC, Li J, Gao J. Functions of galectin-3 and its role in fibrotic diseases. J Pharmacol Exp Ther. 2014;351(2):336–343.
   PubMed Web of Science ®Google Scholar
• Pardo A, Selman M. Matrix metalloproteases in aberrant fibrotic tissue remodeling. Proc Am Thorac Soc. 2006;3(4):383–388.
   PubMedGoogle Scholar
• Rosas IO, Richards TJ, Konishi K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. Plos Med. 2008;5(4):e93.
   PubMed Web of Science ®Google Scholar
• Richards TJ, Park C, Chen Y, et al. Allele-specific transactivation of matrix metalloproteinase 7 by FOXA2 and correlation with plasma levels in idiopathic pulmonary fibrosis. American Journal of Physiology Lung Cellular and Molecular Physiology. 2012;302(8):L746–54.
   PubMed Web of Science ®Google Scholar
• Song JW, Do KH, Jang SJ, et al. Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest. 2013;143(5):1422–1429.
   PubMed Web of Science ®Google Scholar
• Richards TJ, Kaminski N, Baribaud F, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012;185(1):67–76.
   PubMed Web of Science ®Google Scholar
• Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA: Journal Am Med Assoc. 2013;309(21):2232–2239.
   PubMed Web of Science ®Google Scholar
• White ES, Xia M, Murray S, et al. Plasma surfactant protein-D, matrix metalloproteinase-7, and osteopontin index distinguishes idiopathic pulmonary fibrosis from other idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2016;194(10):1242–1251.
   PubMed Web of Science ®Google Scholar
• Tzouvelekis A, Herazo-Maya JD, Slade M, et al. Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis. Respirology. 2016 Oct 19.
   PubMed Web of Science ®Google Scholar
• Nkyimbeng T, Ruppert C, Shiomi T, et al. Pivotal role of matrix metalloproteinase 13 in extracellular matrix turnover in idiopathic pulmonary fibrosis. Plos One. 2013;8(9):e73279.
   PubMed Web of Science ®Google Scholar
• Jenkins RG, Simpson JK, Saini G, et al. Relating longitudinal change in collagen degradation biomarkers to outcome in idiopathic pulmonary fibrosis: an analysis from the prospective, multi-centre PROFILE study. Lancet Respir Med. 2015;3(6):462–472.
   Web of Science ®Google Scholar
• Chien JW, Richards TJ, Gibson KF, et al. Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. Eur Respir J. 2014;43(5):1430–1438.
   PubMed Web of Science ®Google Scholar
• Pardo A, Gibson K, Cisneros J, et al. Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. Plos Med. 2005;2(9):e251.
   PubMed Web of Science ®Google Scholar
• O’Riordan TG, Smith V, Raghu G. Development of novel agents for idiopathic pulmonary fibrosis: progress in target selection and clinical trial design. Chest. 2015;148(4):1083–1092.
   PubMed Web of Science ®Google Scholar
• Lipson KE, Wong C, Teng Y, et al. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair. 2012;5(Suppl 1):S24.
   PubMedGoogle Scholar
• Raghu G, Scholand MB, De Andrade J, et al. FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis. Eur Respir J. 2016;47(5):1481–1491.
   PubMed Web of Science ®Google Scholar
• Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017;66(1):180–190.
   PubMed Web of Science ®Google Scholar
• Jones MG, Richeldi L. Recent advances and future needs in interstitial lung diseases. Semin Respir Crit Care Med. 2016;37(3):477–484.
   PubMed Web of Science ®Google Scholar
• Montgomery RL, Yu G, Latimer PA, et al. MicroRNA mimicry blocks pulmonary fibrosis. EMBO Mol Med. 2014;6(10):1347–1356.
   PubMed Web of Science ®Google Scholar
• Xiao J, Meng XM, Huang XR, et al. miR-29 inhibits bleomycin-induced pulmonary fibrosis in mice. Mol Therapy: Journal Am Soc Gene Ther. 2012;20(6):1251–1260.
   PubMed Web of Science ®Google Scholar